Oncolytics Biotech (NASDAQ:ONCY) Upgraded to “Moderate Buy” at Raymond James
Raymond James upgraded shares of Oncolytics Biotech (NASDAQ:ONCY – Free Report) to a moderate buy rating in a research report released on Thursday morning,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) […]
More Stories
SuRo Capital (NASDAQ:SSSS) & BNY Mellon Strategic Municipal Bond Fund (NYSE:DSM) Head to Head Analysis
BNY Mellon Strategic Municipal Bond Fund (NYSE:DSM – Get Free Report) and SuRo Capital (NASDAQ:SSSS – Get Free Report) are...
LogProStyle Inc. (Kabushiki Kaisha LogProstyle) (LGPS) Announces January 16th IPO
LogProStyle Inc. (Kabushiki Kaisha LogProstyle) (LGPS) expects to raise $12 million in an IPO on Thursday, January 16th, IPO Scoop...
Top humanitarian official issues ceasefire appeal during visit to Gaza City
The UN Humanitarian Coordinator for the Occupied Palestinian Territory called on Sunday for an end to the war in Gaza...
Comparing AGC (OTCMKTS:ASGLY) & Sonic Healthcare (OTCMKTS:SKHHY)
AGC (OTCMKTS:ASGLY – Get Free Report) and Sonic Healthcare (OTCMKTS:SKHHY – Get Free Report) are both mid-cap industrial products companies,...
Comparing South Bow (SOBO) and Its Rivals
South Bow (NYSE:SOBO – Get Free Report) is one of 21 public companies in the “Pipelines, Except Natural Gas” industry,...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...